Evofem Biosciences Past Earnings Performance
Past criteria checks 2/6
Evofem Biosciences has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 64.1% per year.
Key information
13.1%
Earnings growth rate
49.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 64.1% |
| Return on equity | n/a |
| Net Margin | 274.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18Revenue & Expenses BreakdownBeta
How Evofem Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 18 | 50 | 27 | 3 |
| 30 Sep 23 | 14 | 44 | 31 | 3 |
| 30 Jun 23 | 15 | 67 | 43 | 8 |
| 31 Mar 23 | 18 | -48 | 57 | 15 |
| 31 Dec 22 | 17 | -78 | 72 | 25 |
| 30 Sep 22 | 20 | -119 | 92 | 32 |
| 30 Jun 22 | 16 | -283 | 110 | 35 |
| 31 Mar 22 | 11 | -192 | 122 | 36 |
| 31 Dec 21 | 8 | -206 | 138 | 33 |
| 30 Sep 21 | 5 | -194 | 138 | 30 |
| 30 Jun 21 | 3 | -150 | 124 | 25 |
| 31 Mar 21 | 2 | -169 | 110 | 20 |
| 31 Dec 20 | 0 | -142 | 87 | 17 |
| 30 Sep 20 | 0 | -114 | 66 | 14 |
| 30 Jun 20 | 0 | -98 | 53 | 16 |
| 31 Mar 20 | 0 | -81 | 40 | 18 |
| 31 Dec 19 | 0 | -80 | 31 | 22 |
| 30 Sep 19 | 0 | -82 | 27 | 28 |
| 30 Jun 19 | 0 | -87 | 27 | 32 |
| 31 Mar 19 | 0 | -75 | 31 | 39 |
| 31 Dec 18 | 0 | -126 | 34 | 43 |
| 30 Sep 18 | 0 | -131 | 33 | 45 |
| 30 Jun 18 | 0 | -188 | 27 | 41 |
| 31 Mar 18 | 0 | -172 | 18 | 33 |
| 31 Dec 17 | 0 | -109 | 12 | 24 |
| 30 Sep 17 | 0 | -103 | 11 | 17 |
| 31 Dec 16 | 0 | -69 | 15 | 15 |
Quality Earnings: EVFM has a large one-off gain of $75.3M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: EVFM became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EVFM has become profitable over the past 5 years, growing earnings by 13.1% per year.
Accelerating Growth: EVFM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: EVFM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: EVFM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.